Skip to content
DataLookout
Menu

NCT07683013

Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria shortened, about 10 words
    • Start date changed from estimate of Jul 2026 to Aug 3, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Recommended Phase 2 Dose (RP2D) Based on Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT)
Timeframe: Up to 12 weeks after the first dose of the combination therapy

Secondary (5)

Change From Baseline in Prostate-Specific Antigen (PSA) Levels
Maximum Observed Plasma Concentration (Cmax and Cmax,ss) of Niclosamide, Metabolite M1, and Enzalutamide
Area Under the Plasma Concentration-Time Curve (AUCt and AUCtau) of Niclosamide, Metabolite M1, and Enzalutamide
Time to Maximum Observed Plasma Concentration (Tmax and Tmax,ss) of Niclosamide, Metabolite M1, and Enzalutamide
Elimination Half-life (t1/2) of Niclosamide, Metabolite M1, and Enzalutamide

Arms and interventions

Enzalutamide + CP-PCA07Experimental

Patients will receive combination therapy with CP-PCA07 and Enzalutamide. Enzalutamide will be administered orally once daily at a fixed dose of 160 mg. CP-PCA07 will be administered orally three times daily, starting at 600 mg/day, with planned dose escalation to 900 mg/day and 1,200 mg/day according to the protocol-specified 3+3 dose-escalation criteria and dose-limiting toxicity evaluation.

Drugs: CP-PCA07, Enzalutamide 40 mg capsule

Sites

1 site in 1 country

  • Seoul National University HospitalSeoul, South Korea